Logo image of BHVN

BIOHAVEN LTD (BHVN) Stock Fundamental Analysis

NYSE:BHVN - New York Stock Exchange, Inc. - VGG1110E1079 - Common Stock - Currency: USD

16.01  +0.3 (+1.91%)

Premarket: 15.99 -0.02 (-0.12%)

Fundamental Rating

2

BHVN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. BHVN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BHVN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BHVN has reported negative net income.
In the past year BHVN has reported a negative cash flow from operations.
BHVN had negative earnings in each of the past 5 years.
In the past 5 years BHVN always reported negative operating cash flow.
BHVN Yearly Net Income VS EBIT VS OCF VS FCFBHVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

BHVN has a worse Return On Assets (-139.34%) than 83.79% of its industry peers.
The Return On Equity of BHVN (-569.87%) is worse than 78.69% of its industry peers.
Industry RankSector Rank
ROA -139.34%
ROE -569.87%
ROIC N/A
ROA(3y)-101.1%
ROA(5y)-112.04%
ROE(3y)-133.7%
ROE(5y)-344.72%
ROIC(3y)N/A
ROIC(5y)N/A
BHVN Yearly ROA, ROE, ROICBHVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BHVN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BHVN Yearly Profit, Operating, Gross MarginsBHVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

BHVN has more shares outstanding than it did 1 year ago.
BHVN has more shares outstanding than it did 5 years ago.
BHVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BHVN Yearly Shares OutstandingBHVN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
BHVN Yearly Total Debt VS Total AssetsBHVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -6.09, we must say that BHVN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.09, BHVN is not doing good in the industry: 64.66% of the companies in the same industry are doing better.
There is no outstanding debt for BHVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.09
ROIC/WACCN/A
WACCN/A
BHVN Yearly LT Debt VS Equity VS FCFBHVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

2.3 Liquidity

A Current Ratio of 3.82 indicates that BHVN has no problem at all paying its short term obligations.
BHVN has a Current ratio of 3.82. This is comparable to the rest of the industry: BHVN outperforms 43.90% of its industry peers.
A Quick Ratio of 3.82 indicates that BHVN has no problem at all paying its short term obligations.
BHVN has a Quick ratio (3.82) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.82
Quick Ratio 3.82
BHVN Yearly Current Assets VS Current LiabilitesBHVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

BHVN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.28%, which is quite good.
EPS 1Y (TTM)16.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BHVN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.36% yearly.
Based on estimates for the next years, BHVN will show a very strong growth in Revenue. The Revenue will grow by 178.14% on average per year.
EPS Next Y17.24%
EPS Next 2Y14.74%
EPS Next 3Y12.94%
EPS Next 5Y14.36%
Revenue Next Year49.07%
Revenue Next 2Y306.38%
Revenue Next 3Y271.38%
Revenue Next 5Y178.14%

3.3 Evolution

BHVN Yearly Revenue VS EstimatesBHVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
BHVN Yearly EPS VS EstimatesBHVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BHVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BHVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BHVN Price Earnings VS Forward Price EarningsBHVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BHVN Per share dataBHVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as BHVN's earnings are expected to grow with 12.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.74%
EPS Next 3Y12.94%

More info and screens

0

5. Dividend

5.1 Amount

BHVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOHAVEN LTD

NYSE:BHVN (8/18/2025, 9:19:34 PM)

Premarket: 15.99 -0.02 (-0.12%)

16.01

+0.3 (+1.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners87.82%
Inst Owner Change7.92%
Ins Owners11.53%
Ins Owner Change0%
Market Cap1.69B
Analysts86.36
Price Target54.37 (239.6%)
Short Float %13.6%
Short Ratio6.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.05%
Min EPS beat(2)-25.54%
Max EPS beat(2)-0.56%
EPS beat(4)1
Avg EPS beat(4)-9.91%
Min EPS beat(4)-25.54%
Max EPS beat(4)1.84%
EPS beat(8)1
Avg EPS beat(8)-26.79%
EPS beat(12)3
Avg EPS beat(12)-26.01%
EPS beat(16)3
Avg EPS beat(16)-32.21%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.12%
PT rev (3m)-8.45%
EPS NQ rev (1m)2.07%
EPS NQ rev (3m)2.27%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-56.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.58
P/tB 14.75
EV/EBITDA N/A
EPS(TTM)-7.66
EYN/A
EPS(NY)-6.42
Fwd EYN/A
FCF(TTM)-6.11
FCFYN/A
OCF(TTM)-6.1
OCFYN/A
SpS0
BVpS1.27
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -139.34%
ROE -569.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-101.1%
ROA(5y)-112.04%
ROE(3y)-133.7%
ROE(5y)-344.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.6%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.82
Quick Ratio 3.82
Altman-Z -6.09
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.45%
Cap/Depr(5y)891.42%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.7%
EPS Next Y17.24%
EPS Next 2Y14.74%
EPS Next 3Y12.94%
EPS Next 5Y14.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year49.07%
Revenue Next 2Y306.38%
Revenue Next 3Y271.38%
Revenue Next 5Y178.14%
EBIT growth 1Y-2.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.13%
EBIT Next 3Y7.85%
EBIT Next 5Y11.93%
FCF growth 1Y-116.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-120.16%
OCF growth 3YN/A
OCF growth 5YN/A